Circulating Vitamin D Concentration and Risk of Prostate Cancer: a Dose-response Meta-analysis of Prospective Studies

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2018 Feb 2

PMID 29386901

Citations 29

Authors

Jialin Gao

Wei Wei

Gang Wang

Honglan Zhou

Yaowen Fu

Nian Liu

Affiliations

Soon will be listed here.

Abstract

Background: Though many studies have been performed to elucidate the association between circulating vitamin D and prostate cancer, no conclusive result is available. We carried out a dose-response meta-analysis to quantitatively examine the association of circulating 25-hydroxyvitamin D (25[OH]D) concentration with prostate cancer.

Methods: Only prospective studies examining the associations of circulating 25[OH]D concentration with prostate cancer were eligible for the meta-analysis. A random-effect meta-analysis was done first, to calculate the summary relative risk (RR) and 95% confidence intervals (CIs) comparing the higher concentration with the lower concentration of 25[OH]D. A dose-response meta-analysis using random-effects model was then carried out to evaluate the nonlinearity and calculate the summary RR caused per 10 ng/mL increment.

Results: Nineteen prospective cohort or nested case-control studies were included. Higher 25[OH]D concentration was significantly correlated with elevated risk of prostate cancer (RR =1.15, 95% CI 1.06-1.24). No nonlinear relationship was found between 25[OH]D concentration and risk of prostate cancer (=0.654). Dose-response meta-analysis showed that the summary RR caused per 10 ng/mL increment in circulating 25[OH]D concentration was 1.04 (95% CI 1.02-1.06). Subgroup analysis also found a modest dose-response relationship. Funnel plot and Egger's test did not detect publication bias.

Conclusion: The findings suggest that highest 25[OH]D concentration is correlated with elevated risk of prostate cancer and a modest dose-response effect exists in this association; however, more studies are needed.

Citing Articles

Serum 25-Hydroxyvitamin D Levels and Survival Outcomes in Advanced Biliary Tract Cancer: Results From the NIFTY Trial.

Lee S, Cheon J, Kim I, Kim K, Ryoo B, Jeong J Cancer Med. 2025; 14(1):e70560.

PMID: 39749730 PMC: 11696253. DOI: 10.1002/cam4.70560.

Umbrella Review on the Relationship between Vitamin D Levels and Cancer.

Schomann-Finck M, Reichrath J Nutrients. 2024; 16(16).

PMID: 39203855 PMC: 11356988. DOI: 10.3390/nu16162720.

Discordant Health Implications and Molecular Mechanisms of Vitamin D in Clinical and Preclinical Studies of Prostate Cancer: A Critical Appraisal of the Literature Data.

Fendler A, Stephan C, Ralla B, Jung K Int J Mol Sci. 2024; 25(10).

PMID: 38791324 PMC: 11120741. DOI: 10.3390/ijms25105286.

Vitamin D and potential effects on cancers: a review.

Sobhi P, Bahrami M, Mahdizadeh F, Fazaeli A, Babaei G, Rezagholizadeh L Mol Biol Rep. 2024; 51(1):190.

PMID: 38270702 DOI: 10.1007/s11033-023-09111-y.

Association of Single Nucleotide Polymorphism in VDR, GC Globulin and CYP2R1 with the Risk of Esophageal Cancer.

Ali E, Das E, Das P, Kalita M, Dutta K, Kalita S Asian Pac J Cancer Prev. 2023; 24(10):3353-3360.

PMID: 37898838 PMC: 10770657. DOI: 10.31557/APJCP.2023.24.10.3353.

References

Gilbert R, Metcalfe C, Fraser W, Lewis S, Donovan J, Hamdy F . Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. Eur J Cancer Prev. 2012; 22(2):121-5. DOI: 10.1097/CEJ.0b013e3283584954. View

Nayan M, Hamilton R, Macdonald E, Li Q, Mamdani M, Earle C . Vasectomy and risk of prostate cancer: population based matched cohort study. BMJ. 2016; 355:i5546. PMC: 5094198. DOI: 10.1136/bmj.i5546. View

Barnett C, Nielson C, Shannon J, Chan J, Shikany J, Bauer D . Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control. 2010; 21(8):1297-303. PMC: 2903686. DOI: 10.1007/s10552-010-9557-y. View

Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G . Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev. 2015; 96(1):365-408. PMC: 4839493. DOI: 10.1152/physrev.00014.2015. View

Chan J, Stampfer M, Ma J, Gann P, Gaziano J, Pollak M . Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 2002; 94(14):1099-106. DOI: 10.1093/jnci/94.14.1099. View

Nelson S, Batai K, Ahaghotu C, Agurs-Collins T, Kittles R . Association between Serum 25-Hydroxy-Vitamin D and Aggressive Prostate Cancer in African American Men. Nutrients. 2016; 9(1). PMC: 5295056. DOI: 10.3390/nu9010012. View

Choo C, Mamedov A, Chung M, Choo R, Kiss A, Danjoux C . Vitamin D insufficiency is common in patients with nonmetastatic prostate cancer. Nutr Res. 2011; 31(1):21-6. DOI: 10.1016/j.nutres.2010.12.007. View

Trummer C, Pandis M, Verheyen N, Grubler M, Gaksch M, Obermayer-Pietsch B . Beneficial Effects of UV-Radiation: Vitamin D and beyond. Int J Environ Res Public Health. 2016; 13(10). PMC: 5086767. DOI: 10.3390/ijerph13101028. View

Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G . Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer. 2003; 108(1):104-8. DOI: 10.1002/ijc.11375. View

10.

Paller C, Kanaan Y, Beyene D, Naab T, Copeland R, Tsai H . Risk of prostate cancer in African-American men: Evidence of mixed effects of dietary quercetin by serum vitamin D status. Prostate. 2015; 75(13):1376-83. PMC: 4536082. DOI: 10.1002/pros.23018. View

11.

Brandstedt J, Almquist M, Manjer J, Malm J . Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control. 2012; 23(8):1377-85. DOI: 10.1007/s10552-012-9948-3. View

12.

Kelly J, Salles G, Goldman B, Fisher R, Brice P, Press O . Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. J Clin Oncol. 2015; 33(13):1482-90. PMC: 4404425. DOI: 10.1200/JCO.2014.57.5092. View

13.

Grant W . The roles of ultraviolet-B irradiance, vitamin D, apolipoprotein E ε4, and diet in the risk of prostate cancer. Cancer Causes Control. 2010; 22(1):157-8. DOI: 10.1007/s10552-010-9674-7. View

14.

Spratt D, Zumsteg Z, Feng F, Tomlins S . Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol. 2016; 13(10):597-610. PMC: 5030163. DOI: 10.1038/nrclinonc.2016.76. View

15.

Stephan C, Lein M, Matalon J, Kilic E, Zhao Z, Busch J . Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index. J Urol. 2016; 196(3):709-14. DOI: 10.1016/j.juro.2016.03.009. View

16.

Meyer H, Robsahm T, Bjorge T, Brustad M, Blomhoff R . Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. Am J Clin Nutr. 2012; 97(1):147-54. DOI: 10.3945/ajcn.112.039222. View

17.

Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D . Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol. 2011; 175(1):66-73. PMC: 3244608. DOI: 10.1093/aje/kwr265. View

18.

Galunska B, Gerova D, Kosev P, Anakievski D, Hinev A . Serum 25-hydroxy vitamin D levels in Bulgarian patients with prostate cancer: a pilot study. Clin Lab. 2015; 61(3-4):329-35. DOI: 10.7754/clin.lab.2014.140802. View

19.

Yaturu S, Zdunek S, Youngberg B . Vitamin d levels in subjects with prostate cancer compared to age-matched controls. Prostate Cancer. 2013; 2012:524206. PMC: 3530178. DOI: 10.1155/2012/524206. View

20.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View